Name | [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate,sodium |
---|---|
Synonyms |
Nicotinic acid NAD
Deamido NAD Nicotinic acid adenine dinucleotide sodium salt NAAD |
Description | NAAD sodium salt (Deamido nad sodium salt), a functional NAD+ precursor, is the substrate of glutamine-dependent NAD+ synthetase. NAAD sodium salt is used to study the structure of nicotinate mononucleotide adenylyltransferases[1][2]. |
---|---|
Related Catalog | |
In Vitro | In peripheral blood mononuclear cells (PBMC), NAAD is only expected to be produced in biosynthesis of NAD+ from tryptophan and NA2, was elevated from less than 20 nM to as high as 0.91 μM[1]. Nicotinamide adenine dinucleotide synthetases (NADS) catalyze the amidation of nicotinic acid adenine dinucleotide (NAAD) to yield the enzyme cofactor nicotinamide adenine dinucleotide (NAD)[2]. |
In Vivo | In mice, when nicotinic acid (NA) is provided by oral gavage, liver NA peaked (340 pmol/mg) in 15 min. Hepatic NA appearance is followed by an expected peak of 220 NAAD at 1 h post gavage and a rise in hepatic NAD+ from 990 baseline to 2200 at 2 h[1]. NAAD is reported in mouse liver when 500 mg/kg of radioactive nicotinamide (Nam) is injected intraperitoneally (IP) into the body cavity of mice. However, NAAD is observed in kidneys, ovaries, lung, heart and brain in addition to liver in mice IP-injected with 500 mg/kg of NA but not Nam[1]. |
References |
Molecular Formula | C21H25N6NaO15P2 |
---|---|
Molecular Weight | 686.39 |
Exact Mass | 686.07500 |
PSA | 337.75000 |
Storage condition | 20°C |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi: Irritant; |
Risk Phrases | 36/37/38 |
Safety Phrases | 26-36 |
RIDADR | NONH for all modes of transport |